Vista Pharmaceuticals (524711) Q4 24/25 earnings summary

Executive summary

• Audited financial results for the quarter and year ended 31 March 2025 were approved, with an unmodified opinion from statutory auditors.

• Appointments of new internal and secretarial auditors for FY 2025-26 and FY 2025-26 to 2029-30, respectively, were confirmed.

• WHO Certificate awarded to the company, effective as of the results release date.

Financial highlights

• Revenue from operations for Q4 FY25 was ₹323.00 lakhs, up from ₹255.5 lakhs in Q3 FY25 and ₹313.25 lakhs in Q4 FY24.

• Net loss for Q4 FY25 stood at ₹149.57 lakhs, compared to a net loss of ₹132.23 lakhs in Q3 FY25 and net profit of ₹9.07 lakhs in Q4 FY24.

• For FY25, total income was ₹1,051.52 lakhs, with a net loss of ₹464.87 lakhs, compared to FY24 total income of ₹1,062.12 lakhs and net loss of ₹451.20 lakhs.

• Basic and diluted EPS for FY25 was (₹0.79), compared to (₹0.74) in FY24.

Key financial ratios and metrics

• Paid-up equity share capital increased to ₹1,231.04 lakhs as of 31 March 2025, from ₹943.30 lakhs a year earlier.

• Total equity rose to ₹4,542.25 lakhs as of 31 March 2025, up from ₹4,046.23 lakhs as of 31 March 2024.

• Cash and cash equivalents at year-end were ₹73.33 lakhs, up from ₹9.44 lakhs at the previous year-end.